care@investkraft.com
+91-9599071040
+91-9797971876
Download RHP
Latest GMP
- Lead Manager
- JM Financial Limited
- IPO Open Date
- 24th Aug 2026
- IPO Close Date
- 27th Aug 2026
- Allotment date
- 28th Aug 2026
- Listing date
- 1st Sep 2026
- Issue Size
- ₹ 1757 Cr.
- Issue Price Band
- ₹ 938 to 988
- Lot Size
- 15 Share
- Minimum Investment
- ₹ 14820
Disclaimer: IPO details, GMP, subscription figures, and other related information are for informational purposes only and may not always be accurate or up to date. Please verify the latest details from official sources before investing.
About Symbiotec Pharmalab Limited
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.
Manufacturing Capabilities
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with:
- Maximum chemical synthesis capacity of 584.67 metric tonnes (MT)
- Fermentation capacity of 300 kilolitres
Business Focus
Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
Competitive Strengths
- Global leadership in corticosteroid and steroidal hormone APIs
- Long-standing relationships with domestic and international customers
- Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record
- Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers
- Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings
IPO Subscription Details
| Category | Shares Offered | Shares Applied | Subscription Times (x) |
|---|
Grey Market Premium (GMP)
| GMP Date | IPO Price | GMP | Estimated Listing Price | Estimated Profit* | Last Updated |
|---|
Financials of Symbiotec Pharmalab Limited
A quick overview of the key financial performance of Symbiotec Pharmalab Limited.
Total Assets (₹ Cr)
Revenue (₹ Cr)
Profit after Tax (₹ Cr)
*All values are in Rs. Cr
Company Financials
Revenue increased by 15%, Profit after Tax (PAT) increased by 14%, Total Assets increased by 13% between FY2025 and FY2026.
| Period Ended | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 723.33 | 755.98 | 872.26 |
| Assets | 1,294.79 | 1,579.65 | 1,780.79 |
| Total Income | 723.33 | 755.98 | 872.26 |
| Profit After Tax | 100.05 | 96.78 | 109.90 |
| EBITDA | 177.04 | 206.11 | 231.97 |
| Net Worth | 720.68 | 821.15 | 1,158.64 |
| Reserves & Surplus | 704.11 | 803.96 | 1,137.18 |
| Total Borrowings | 247.21 | 540.92 | 387.91 |
IPO Lot Size
Application
Lots
Shares
Amount
Retail (Min)
1
15
₹ 14,820
Retail (Max)
13
195
₹ 1,92,660
S-HNI (Min)
14
210
₹ 2,07,480
S-HNI (Max)
67
1,005
₹ 9,92,940
B-HNI (Min)
68
1,020
₹ 10,07,760
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹ 14,820 |
| Retail (Max) | 13 | 195 | ₹ 1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹ 2,07,480 |
| S-HNI (Max) | 67 | 1,005 | ₹ 9,92,940 |
| B-HNI (Min) | 68 | 1,020 | ₹ 10,07,760 |
Key Performance Indicators (KPI)
| KPI | Latest |
|---|---|
| ROE (%) | 11.19 |
| ROCE (%) | 11.56 |
| PAT Margin (%) | 12.6 |
| EBITDA Margin (%) | 26.59 |
|
Pre IPO
Post IPO
|
|
| EPS (₹) |
17.82
17.39
|
| P/E (x) |
55.44
56.81
|
| Promoter Holding (%) |
28.8
-
|
| Market Cap | 6094 |
IPO Lead Manager(s)
Lead Manager Details
- JM Financial Limited
- Contact Person: Prachee Dhuri
- SEBI Registration Number: INM000010361
- Investor Grievance Email: grievance.ibd@jmfl.com
- Website: https://www.jmfl.com
- Email: symbiotec.ipo@jmfl.com
- Phone: +91 22 6630 3030
- Address: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, Maharashtra, India
Lead Manager Details
- Avendus Capital Private Limited
- Contact Person: Sarthak Sawa / Ananya Chawla
- SEBI Registration Number: INM000011021
- Investor Grievance Email: investorgrievance@avendus.com
- Website: https://www.avendus.com
- Email: symbiotec.ipo@avendus.com
- Phone: +91 22 6648 0050
- Address: Platina Building, 9th Floor, 901, Plot No C-59, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India
Lead Manager Details
- Motilal Oswal Investment Advisors Limited
- Contact Person: Kunal Thakkar / Vaibhav Shah
- SEBI Registration Number: INM000011005
- Investor Grievance Email: moiaplredressal@motilaloswal.com
- Website: https://www.motilaloswal.com
- Email: spl.ipo@motilaloswal.com
- Phone: +91 22 7193 4380
- Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai – 400 025, Maharashtra, India
Lead Manager Details
- Nomura Financial Advisory and Securities (India) Private Limited
- Contact Person: Vishal Kanjani / Chirag Shah
- SEBI Registration Number: INM000011419
- Investor Grievance Email: investorgrievances-in@nomura.com
- Website: https://www.nomuraholdings.com/company/group/asia/india/index.html
- Email: symbiotecipo@nomura.com
- Phone: +91 22 4037 4037
- Address: Ceejay House, Level 11, Plot F, Shiv Sagar Estate, Dr. Annie Besant Marg, Worli, Mumbai – 400 018, Maharashtra, India
IPO Registrar
- Registrar Name
- MUFG Intime India Private Limited (Formerly Link Intime India Private Limited)
- Phone
- +91 810 811 4949
- Contact Person
- Shanti Gopalkrishnan
- SEBI Registration Number
- INR000004058
- Address
- C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
- Website
- https://in.mpms.mufg.com/
Company Contact Details
- Company Name
- Symbiotec Pharmalab Limited
- Phone
- +91 731 667 6405
- Contact Person
- Salil Jain
- Corporate Identity Number
- U24232MP2002PLC015293
- Address
- 385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India
- Website
- https://www.symbiotec.com/
Symbiotec Pharmalab Limited FAQs
